本文由小咖机器人翻译整理

期刊来源：BMJ

原文链接：https://doi.org/10.1136/bmj-2023-075859

摘要内容如下：

除了传统的放化疗和靶向癌症治疗外，基于免疫的疗法，特别是免疫检查点抑制剂（ICIs）和嵌合抗原受体T细胞疗法（CAR-T）的使用在广泛的癌症中呈指数级增长。与此平行的是对脱靶免疫相关不良事件的识别，这些不良事件几乎可以影响包括心血管系统在内的任何器官系统。ICIS的使用与心肌炎（一种不常见但高度致命的不良反应）、心包炎和心包积液、血管炎、血栓栓塞和潜在的加速动脉粥样硬化有关。导致全身性细胞因子释放综合征的CAR-T与多种心血管后果有关，包括心律失常、心肌梗死和心力衰竭。这篇综述总结了与ICIS和CAR-T相关的心血管不良反应的知识现状。

英文原文如下：

Abstracts

In addition to conventional chemoradiation and targeted cancer therapy, the use of immune based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (CAR-T), has increased exponentially across a wide spectrum of cancers. This has been paralleled by recognition of off-target immune related adverse events that can affect almost any organ system including the cardiovascular system. The use of ICIs has been associated with myocarditis, a less common but highly fatal adverse effect, pericarditis and pericardial effusions, vasculitis, thromboembolism, and potentially accelerated atherosclerosis. CAR-T resulting in a systemic cytokine release syndrome has been associated with myriad cardiovascular consequences including arrhythmias, myocardial infarction, and heart failure. This review summarizes the current state of knowledge regarding adverse cardiovascular effects associated with ICIs and CAR-T.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。